Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical Autonomic Research
Published in: Clinical Autonomic Research 1/2017

Open Access 01-07-2017 | Case Vignette

Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease

Authors: Daniel Kremens, Mark Lew, Daniel Claassen, Brent P. Goodman

Published in: Clinical Autonomic Research | Special Issue 1/2017

Login to get access

Excerpt

Is it appropriate to add droxidopa in a patient already taking fludrocortisone or midodrine? Should droxidopa substitute any of the previous treatments? …
Literature
1.
Elgebaly A, Abdelazeim B, Mattar O, Gadelkarim M, Salah R, Negida A (2016) Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension. Clin Auton Res Off J Clin Auton Res Soc 26:171–180CrossRef
2.
Fanciulli A, Gobel G, Ndayisaba JP, Granata R, Duerr S, Strano S, Colosimo C, Poewe W, Pontieri FE, Wenning GK (2016) Supine hypertension in Parkinson’s disease and multiple system atrophy. Clin Auton Res Off J Clin Auton Res Soc 26:97–105CrossRef
3.
Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G (2015) Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson’s disease (nOH306B). Mov Disord Off J Mov Disord Soc 30:646–654CrossRef
4.
Kaufmann H, Norcliffe-Kaufmann L, Palma JA (2015) Droxidopa in neurogenic orthostatic hypotension. Expert Rev Cardiovas Ther 13:875–891CrossRef
5.
Smith W, Wan H, Much D, Robinson AG, Martin P (2016) Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study. Clin Auton Res Off J Clin Auton Res Soc 26:269–277CrossRef
6.
Umehara T, Matsuno H, Toyoda C, Oka H (2016) Clinical characteristics of supine hypertension in de novo Parkinson disease. Clin Auton Res Off J Clin Auton Res Soc 26:15–21CrossRef
Metadata
Title
Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease
Authors
Daniel Kremens
Mark Lew
Daniel Claassen
Brent P. Goodman
Publication date
01-07-2017
Publisher
Springer Berlin Heidelberg
Published in
Clinical Autonomic Research / Issue Special Issue 1/2017
Print ISSN: 0959-9851
Electronic ISSN: 1619-1560
DOI
https://doi.org/10.1007/s10286-017-0434-6

Other articles of this Special Issue 1/2017

Clinical Autonomic Research 1/2017 Go to the issue

Editorial

Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?

Case Vignette

Differential diagnosis of suspected neurogenic orthostatic hypotension in a patient with Parkinson disease

Case Vignette

Managing neurogenic orthostatic hypotension with droxidopa in a patient with Parkinson disease, atrial fibrillation, and hypertension

Case Vignette

Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy

Editorial

Neurogenic orthostatic hypotension: the very basics

Case Vignette

Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus